Table 1 Patient characteristics
Local recurrence | p value | ||||
|---|---|---|---|---|---|
+ (n = 12) | − (n = 375) | ||||
n | % | n | % | ||
Age | 0.065 | ||||
≤ 40 | 5 | 41.7 | 71 | 18.9 | |
> 40 | 7 | 58.3 | 304 | 81.1 | |
MRI findings before reconstruction | 0.482 | ||||
Segmental lesion | 11 | 91.7 | 350 | 93.3 | |
Isolated mass | 1 | 8.3 | 19 | 5.1 | |
NE | 0 | 0.0 | 6 | 1.6 | |
Histology | 0.408 | ||||
DCIS/LCIS | 3 | 25.0 | 84 | 22.4 | |
IDC/ILC | 5 | 41.7 | 266 | 70.9 | |
Other | 4 | 33.3 | 25 | 6.7 | |
Tumor size | 0.470 | ||||
Is | 3 | 25.0 | 86 | 22.9 | |
1 | 4 | 33.3 | 184 | 49.1 | |
2 | 5 | 41.7 | 89 | 23.7 | |
3 | 0 | 0.0 | 16 | 4.3 | |
Nodal status | 0.432 | ||||
0 | 8 | 66.7 | 301 | 80.3 | |
1 | 4 | 33.3 | 65 | 17.3 | |
2/3 | 0 | 0.0 | 9 | 2.4 | |
Stage | 0.842 | ||||
0 | 3 | 25.0 | 86 | 22.9 | |
I | 4 | 33.3 | 158 | 42.1 | |
II | 5 | 41.7 | 117 | 31.2 | |
III | 0 | 0.0 | 14 | 3.7 | |
ER | 0.400 | ||||
+ | 9 | 75.0 | 320 | 85.3 | |
− | 3 | 25.0 | 55 | 14.7 | |
PgR | 0.867 | ||||
+ | 9 | 75.0 | 289 | 77.1 | |
− | 3 | 25.0 | 86 | 22.9 | |
HER2 | 0.453 | ||||
+ | 3 | 25.0 | 65 | 17.3 | |
− | 9 | 75.0 | 306 | 81.6 | |
NE | 0 | 0.0 | 4 | 1.1 | |
Subtype | 0.552 | ||||
Luminal A-like | 6 | 50.0 | 235 | 62.7 | |
Luminal B-like HER2 negative | 3 | 25.0 | 59 | 15.7 | |
Luminal B-like HER2 positive/HER2 | 3 | 25.0 | 59 | 15.7 | |
Triple Negative | 0 | 0.0 | 15 | 4.0 | |
NE | 0 | 0.0 | 7 | 1.9 | |
Nuclear grade | 0.402 | ||||
Low/intermediate/high grade DCIS | 3 | 25.0 | 70 | 18.7 | |
1 | 3 | 25.0 | 154 | 41.1 | |
2/3 | 6 | 50.0 | 125 | 33.3 | |
NE | 0 | 0.0 | 26 | 6.9 | |
EIC | 0.981 | ||||
+ | 4 | 33.3 | 115 | 30.7 | |
− | 4 | 33.3 | 117 | 31.2 | |
NE | 4 | 33.3 | 143 | 38.1 | |
Lymphatic vessel invasion | 0.004 | ||||
+ | 9 | 75.0 | 122 | 32.5 | |
− | 3 | 25.0 | 247 | 65.9 | |
NE | 0 | 0.0 | 6 | 1.6 | |
Operation | 0.393 | ||||
TM/SSM | 10 | 83.3 | 334 | 89.1 | |
NSM | 1 | 8.3 | 13 | 3.5 | |
ASM | 1 | 8.3 | 28 | 7.5 | |
Surgical margin (lateral) | 0.476 | ||||
+ | 1 | 8.3 | 13 | 3.5 | |
< 2 mm | 0 | 0.0 | 6 | 1.6 | |
− | 11 | 91.7 | 356 | 94.9 | |
NE | 0 | 0 | 0 | 0 | |
Surgical margin (vertical) | 0.007 | ||||
+ | 1 | 8.3 | 22 | 5.9 | |
< 2 mm | 8 | 66.7 | 104 | 27.7 | |
− | 1 | 8.3 | 170 | 45.3 | |
NE | 2 | 16.7 | 79 | 21.1 | |
Adjuvant PMRT | 1.000 | ||||
+ | 0 | 0.0 | 12 | 3.2 | |
− | 12 | 100.0 | 363 | 96.8 | |
Neoadjuvant chemotherapy | 1.000 | ||||
+ | 0 | 0.0 | 21 | 5.6 | |
− | 12 | 100.0 | 354 | 94.4 | |
Adjuvant hormonal therapy | 0.340 | ||||
+ | 7 | 58.3 | 268 | 71.5 | |
− | 5 | 41.7 | 107 | 28.5 | |
Any chemotherapy ± Trastuzumab | 0.535 | ||||
+ | 5 | 41.7 | 120 | 32.0 | |
− | 7 | 58.3 | 255 | 68.0 | |